Alps Advisors Inc. increased its position in shares of Molecular Templates Inc. (NASDAQ:MTEM) by 21.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,052 shares of the biotechnology company’s stock after purchasing an additional 6,265 shares during the quarter. Alps Advisors Inc. owned approximately 0.13% of Molecular Templates worth $288,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in shares of Molecular Templates during the fourth quarter worth approximately $722,000. Lyon Street Capital LLC purchased a new stake in Molecular Templates in the 4th quarter valued at $557,000. BlueCrest Capital Management Ltd purchased a new stake in Molecular Templates in the 4th quarter valued at $157,000. Two Sigma Investments LP purchased a new stake in Molecular Templates in the 4th quarter valued at $131,000. Finally, Paloma Partners Management Co purchased a new stake in Molecular Templates in the 4th quarter valued at $113,000. Hedge funds and other institutional investors own 15.88% of the company’s stock.
Several analysts have issued reports on MTEM shares. ValuEngine cut Molecular Templates from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. BidaskClub cut Molecular Templates from a “buy” rating to a “hold” rating in a report on Wednesday, February 7th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Molecular Templates has an average rating of “Hold” and an average price target of $5.20.
Molecular Templates (NASDAQ:MTEM) last issued its earnings results on Monday, May 14th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.07). The company had revenue of $0.48 million during the quarter. Molecular Templates had a negative net margin of 514.16% and a negative return on equity of 40.24%. equities analysts expect that Molecular Templates Inc. will post -1.12 earnings per share for the current fiscal year.
About Molecular Templates
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.